Still no ad­u­canum­ab fil­ing and an in-house gath­er­ing trig­gered a health dis­as­ter, but Bio­gen's CEO nev­er­the­less took home record pay

2020 got off to one of the most night­mar­ish starts in the in­dus­try at Bio­gen $BI­IB as an an­nu­al meet­ing for its glob­al ex­ecs turned in­to a “su­per­spread­er” event that trig­gered a string of Covid-19 in­fec­tions in Mass­a­chu­setts and around the world.

But that didn’t get in the way of some nice bumps in com­pen­sa­tion for the ex­ec­u­tive crew that runs the com­pa­ny — where a con­tentious ar­gu­ment over its Phase III Alzheimer’s study con­tin­ues to spark anger and sup­port from every cor­ner.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER